Immune checkpoint blockade (ICB) targeting pathways like PD-1, PD-L1, and CTLA-4 has revolutionized cancer treatment, but determining which patients will benefit remains a significant clinical challenge. Previous research established the anaplastic lymphoma kinase (ALK) gene as a key oncogenic driver, but the role of immunotherapy in patients with ALK-altered tumors has been controversial, particularly due to the profound heterogeneity between ALK rearrangements and somatic mutations

Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment of breast cancer.

Scientists at Oregon Health & Science University have developed a new technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer.

A genomic study of the largest pediatric and adult aplastic anemia cohort genetically profiled to date, finds that protective mutations arise as independent events in different stem cells years before diagnosis. 

A new study shows that how a cell fails to divide after copying its DNA can determine its fate.

Advanced technologies are helping researchers identify environmental contaminants that could potentially be contributing to the rising incidence of early-onset colorectal cancer. However, epigenetic studies on such associations should be interpreted with caution, according to researchers at Dana-Farber Cancer Institute, who are leading experts in the disease.

A new pretargeted radioimmunotherapy (PRIT) technique has been shown to be safe and effective in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues. This research was published in the May issue of The Journal of Nuclear Medicine.

UC San Diego biologists have identified a way to reinvigorate immune system cells, which can become exhausted after fighting disease. They found that protein recycling malfunctions after a cell burns out. Restoring a proper recycling system allows T cells to regain their cancer-fighting functions.

This minimally invasive and cost-effective alternative to tissue biopsy offers “an accessible tool for tailoring treatment strategies in breast cancer,” researchers reported in the journal Science Translational Medicine.